Moderna reports effective results from influenza vaccine trial

photoman

Moderna (NASDAQ:MRNA), on Monday, reported positive results from a late-stage study comparing its influenza vaccine candidate, mRNA-1010, to a standard vaccine in adults aged 50 and older.

The results showed that mRNA-1010 met the highest effectiveness standard set in the